A Phase I Study of SNH-119014 in Healthy Volunteers

Key facts

Sponsor

ScinnoHub Pharmaceutical Co., Ltd.

Intervention

SNH-119014(drug)

Enrollment

96 enrolled

Eligibility

18-45 years · All sexes

Timeline

2025 – 2026

Study locations (1)

• The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06886477
  Sickle Cell, Pain and Mediterranean Diet
  University of Illinois at Chicago
• RECRUITINGPHASE1, PHASE2NCT06144749
  A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
  Hillhurst Biopharmaceuticals, Inc.
• RECRUITINGNANCT07064941
  Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
  University of California, San Francisco
• ACTIVE NOT RECRUITINGNANCT06800495
  Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Screening
  Universiti Teknologi Mara
• ENROLLING BY INVITATIONNCT07003256
  Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
  Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06481306
  A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  Bristol-Myers Squibb
• RECRUITINGNANCT06031714
  Fetal Cell Receptors Repertoire
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06071377
  Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
  National Alliance for Sickle Cell Centers

See all trials for Genetic hemoglobinopathy →